A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state
- 1 July 1986
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 22 (3) , 191-196
- https://doi.org/10.1007/bf00200032
Abstract
Summary Studies were performed on the activation of human blood monocytes to the antitumor state by a dried preparation of multilamellar vesicle (MLV) liposomes in which synthetic muramyl tripeptide phosphatidylethanolamine (MTP-PE) was inserted directly into the liposome membrane. Dried liposomes composed of synthetic phospholipids [phosphatidylcholine (PC) and phosphatidylserine (PS) in a molar ratio of 7:3] were prepared by lyophilization. Dried liposome-MTP-PE was found to be superior in several ways to free desmethyl muramyl dipeptide (norMDP) or conventional liposome-MTP-PE, prepared immediately before use. First, dried lipsome-MTP-PE was stable and strongly activated monocytes when stored for over 3 months in a freezer at −°C or even in suspension at 4°C. Second, human monocytes in suspension, as well as in the adherent form, were activated to the tumoricidal state by interaction for at least 4 h with the dried preparation of liposome-MTP-PE. Third, monocytes activated with the dried liposome-MTP-PE or conventionally prepared liposome-MTP-PE maintained their tumoricidal activity for a longer period (4 days) than those activated with free norMDP. These results indicate that the dried preparation of liposome-MTP-PE can be stored for a long time, has a reproducible effect that can be standardized and should be valuable for in situ activation of human monocytes to the tumoricidal state, which is associated with eradication of cancer metastases.Keywords
This publication has 24 references indexed in Scilit:
- Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic stateCancer Immunology, Immunotherapy, 1984
- Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.The Journal of Immunology, 1984
- POTENTIAL VALUE OF LIPOSOMES CONTAINING MURAMYL DIPEPTIDE FOR AUGMENTING THE TUMORICIDAL ACTIVITY OF HUMAN ALVEOLAR MACROPHAGES1984
- Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.Journal of Clinical Investigation, 1983
- The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.The Journal of Immunology, 1983
- ACTIVATION OF TUMORICIDAL PROPERTIES IN HUMAN-BLOOD MONOCYTES BY LIPOSOMES CONTAINING LIPOPHILIC MURAMYL TRIPEPTIDE1983
- INVOLVEMENT OF MACROPHAGES IN THE ERADICATION OF ESTABLISHED METASTASES FOLLOWING INTRAVENOUS-INJECTION OF LIPOSOMES CONTAINING MACROPHAGE ACTIVATORS1982
- Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proceedings of the National Academy of Sciences, 1981
- In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomesCellular Immunology, 1981
- The pathogenesis of cancer metastasisNature, 1980